NCT02094235

A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 2 Years – 15 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, double-blind, vehicle-control study of 0.05% and 0.2% E6005 ointment. Pediatric subjects with atopic dermatitis (AD) will be grouped into two; an elder group (childhood - adolescent: 7 to 15 years of age) and a younger group (children: 2 to 6 years of age) according to the sequential cohorts by confirming the safety.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	E6005 0.05%
DRUG	Placebo	0.5 g placebo ointment
DRUG	E6005 0.2%

Timeline

• Start date: 2014-01-01
• Primary completion: 2014-12-01
• Completion: 2015-01-01
• First posted: 2014-03-21
• Last updated: 2025-06-04

Locations

3 sites across 1 country: Japan